Big Health, a San Francisco, CA-based provider of non-drug digital treatments for mental health, has acquired Limbix, creators of an evidence-based digital therapeutic for teens and young adults with symptoms of depression.
The amount of the deal was not disclosed.
Since its founding in 2016, Limbix has raised $30 million through its Series A funding round and has built a research-based pipeline of adolescent products. As a result of the transaction, Big Health’s therapeutic portfolio expands to include SparkRx for adolescent depression and an adolescent anxiety product in development, alongside its flagship programs for patients aged 18+: Sleepio, for insomnia, and Daylight, for anxiety.
SparkRx is designed to overcome common barriers to mental health care access, meeting young people on their smartphones, and is supported by trial data demonstrating a clinically meaningful reduction in depression symptoms. The self-guided, cognitive behavioral therapy (CBT) based treatment for those aged 13+ teaches skills such as mood tracking, behavioral activation, problem solving and mindfulness. It was developed by an interdisciplinary team, including experts in adolescent psychology.
Led by CEO Arun Gupta, Big Health provides digital therapies that expand access to standard care, including behavioral medicine, and are backed by more than 80 research and 15 randomized controlled trials. The solution integrates across the entire care journey, from member engagement to billing through pharmacy benefit managers.
In addition to health care providers, SparkRx will be made available to Big Health’s employer, public sector, health systems and health plan customers, and through the company’s strategic distribution agreements with pharmacy benefit managers (PBMs), increasing nationwide access. To date, more than 300,000 patients have enrolled in treatment through one of Big Health’s digital therapeutics.
FinSMEs
17/07/2023